Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer (FORTIS-C)
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor: Agennix
Listed as NCT00706862, this PHASE3 trial focuses on Non Small Cell Lung Cancer and remains ongoing. Sponsored by Agennix, it has been updated 8 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
-
Feb 2017 — May 2017 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agennix
For direct contact, visit the study record on ClinicalTrials.gov .